July 17, 2026 — RNews

#lymphoma — Friday, July 17, 2026 (1 items)

hot top new

← prev day next day →

0

Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study. (linkinghub.elsevier.com)

Wu G … Shentu J iScience 2026-07-17

#lymphoma #kinase inhibitor #clinical trial #hematologic malignancy #pharmacokinetics